Full Text View
Tabular View
No Study Results Posted
Related Studies
Spiriva® Assessment of FEV1 (SAFE)
This study has been completed.
Study NCT00277264   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on January 9, 2006.   Last Updated on May 14, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Respiration Disorders
More general conditions related to this trial
Disease Attributes
Lung Diseases, Obstructive
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
Tiotropium (Spiriva®)
Additional drug interventions recognized in this trial
Tiotropium
More general drug interventions related to this trial
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services